EPRX
NASDAQ · Biotechnology
Eupraxia Pharmaceuticals Inc
$7.08
+0.19 (+2.76%)
Open$7.05
Previous Close$6.89
Day High$7.51
Day Low$7.04
52W High$12.86
52W Low$3.96
Volume—
Avg Volume66.8K
Market Cap645.78M
P/E Ratio—
EPS$-0.82
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+526.3% upside
Current
$7.08
$7.08
Target
$44.34
$44.34
$25.23
$44.34 avg
$48.95
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 121.08M | 121.80M | 129.11M |
| Net Income | -20,292,332 | -19,070,968 | -17,081,441 |
| Profit Margin | -16.8% | -15.7% | -13.2% |
| EBITDA | -26,386,283 | -29,891,368 | -27,935,877 |
| Free Cash Flow | -23,062,869 | -20,449,670 | -23,278,243 |
| Rev Growth | +21.7% | +19.1% | -8.5% |
| Debt/Equity | 0.16 | 0.18 | 0.19 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |